This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Neuropathology  • Alert me on articles by topic  Social Bookmarking   What's this?

Åse Mygland, MD PhD; Per Monstad, MD

Arch Neurol. 2003;60:260-264.

Objectives  To study a representative group of patients with chronic acquired symmetric demyelinating polyneuropathies, and to evaluate classification by pattern of weakness and by presence of immunoglobulin monoclonal protein (M protein).

Methods  In Vest-Agder County, Norway, an unselected population of patients with chronic symmetric polyneuropathies who fulfill electrodiagnostic criteria for demyelination are registered in a database and followed up prospectively. Data were taken from the database on April 2, 2001. Patients with proximal as well as distal weakness were classified as having chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and patients with only distal symptoms as having distal acquired demyelinating symmetric polyneuropathy (DADS).

Results  A total of 29 patients had chronic acquired symmetric demyelinating polyneuropathy; 15 had CIDP and 14 had DADS. The 2 categories differed regarding spinal protein level (mean ± SD, 0.102 ± 0.060 g/dL in CIDP vs 0.065 ± 0.029 g/dL in DADS; P = .05); clinical course (remitting in 6 of 13 patients with CIDP vs 0 of 14 with DADS; P = .02); disability score at diagnosis (mean ± SD, 3.3 ± 1.0 in CIDP vs 1.9 ± 0.6 in DADS; P<.001) and at peak of symptoms (mean ± SD, 3.6 ± 1.1 in CIDP vs 2.3 ± 0.6 in DADS; P<.001); and response to immunosuppressive treatment (11 of 12 patients with CIDP vs 2 of 7 with DADS; P = .01). An M protein was detected in 8 patients (3 with CIDP and 5 with DADS). Patients with polyneuropathy with and without M protein were similar in clinical features, course, disability, and treatment response.

Conclusion  Classification by presence or absence of proximal weakness separates patients with chronic acquired symmetric demyelinating polyneuropathy into groups that are different in clinical course, disability, and treatment response.

From the Department of Neurology, Vest-Agder Central Hospital (Drs Mygland and Monstad), and Spesialsykehuset for Rehabilitering HF (Dr Mygland), Kristiansand, Norway.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy
Tackenberg et al.
Neurology 2007;68:1622-1629.
ABSTRACT | FULL TEXT  

Chronic Inflammatory Demyelinating Polyneuropathy
Koller et al.
NEJM 2005;352:1343-1356.
FULL TEXT